[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610439":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":63,"centralContacts":67,"locations":73,"responsibleParty":467,"collaborators":469,"id":472,"slug":52,"hasResults":473,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":52,"eligibilityCriteria":477,"healthyVolunteers":473,"sex":478,"minAge":479,"maxAge":52,"enrollmentInfo":480,"targetDuration":52,"studyType":483,"phases":484,"briefSummary":487,"conditions":488,"keywords":52,"overallStatus":76,"whyStopped":52,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":499},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,16,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1, Parts A and B: Gocataming + I-DXd","EXPERIMENTAL","Participants who completed standard of care (SOC) induction chemotherapy with concurrent approved anti-programmed cell death 1\u002Fligand 1 protein (anti-PD-1\u002FL1) treatment for ES-SCLC and did not have disease progression per investigator discretion, will receive gocatamig and I-DXd in the maintenance phase, until documented disease progression or meeting other study discontinuation criteria.",[13,14,15],"Drug: Gocatamig","Drug: I-DXd","Drug: Rescue Medications",{"label":17,"type":10,"description":18,"interventionNames":19},"Arm 2, Parts A and B: Gocataming + I-DXd","Participants who did not receive prior systemic treatment for ES-SCLC will receive gocatamig and I-DXd during induction and maintenance phases, until documented disease progression or meeting other study discontinuation criteria.",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Arm 3, Part B: Gocataming + I-DXd → gocatamig + atezolizumab","Participants who did not receive prior systemic treatment for ES-SCLC will receive gocatamig and I-DXd in the induction phase, followed by gocatamig and atezolizumab in the maintenance phase, until documented disease progression or meeting other study discontinuation criteria.",[13,14,24,15],"Drug: Atezolizumab",{"label":26,"type":27,"description":28,"interventionNames":29},"Arm 4, Part B: Carboplatin + etoposide + atezolizumab → atezolizumab","ACTIVE_COMPARATOR","Participants who did not receive prior systemic treatment for ES-SCLC will receive SOC (carboplatin + etoposide + atezolizumab) in the induction phase, followed by atezolizumab in the maintenance phase, until documented disease progression or meeting other study discontinuation criteria.",[24,30,31],"Drug: Carboplatin","Drug: Etoposide",[33,42,49,53,56,59],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"DRUG","Gocatamig","Intravenous (IV) administration",[9,17,21],[39,40,41],"MK-6070","HPN328","DS-3280",{"type":34,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"I-DXd","IV administration",[9,17,21],[47,48],"MK-2400","DS-7300a",{"type":34,"name":50,"description":44,"armGroupLabels":51,"otherNames":52},"Atezolizumab",[21,26],null,{"type":34,"name":54,"description":44,"armGroupLabels":55,"otherNames":52},"Carboplatin",[26],{"type":34,"name":57,"description":44,"armGroupLabels":58,"otherNames":52},"Etoposide",[26],{"type":34,"name":60,"description":61,"armGroupLabels":62,"otherNames":52},"Rescue Medications","Participants will receive rescue medications at the investigator's discretion. Recommended rescue medications include tocilizumab for treatment of cytokine release syndrome (CRS); dexamethasone, acetaminophen, and diphenhydramine for CRS\u002Finfusion-related reaction (IRR) prophylaxis; and 5-hydroxytryptamine 3 (5-HT3) receptor antagonist, neurokinin 1 (NK-1) receptor antagonist, and corticosteroid for prevention of nausea and vomiting.",[9,17,21],[64],{"name":65,"affiliation":5,"role":66},"Medical Director","STUDY_DIRECTOR",[68],{"name":69,"role":70,"phone":71,"phoneExt":52,"email":72},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[74,91,104,117,130,143,156,169,182,194,206,219,232,241,253,267,276,285,299,312,324,337,350,363,376,388,401,413,426,435,444,453],{"facility":75,"status":76,"city":77,"state":78,"zip":79,"country":80,"cosmosGeoPoint":81,"geoPoint":86,"contacts":87},"Providence Medical Foundation ( Site 0124)","RECRUITING","Santa Rosa","California","95403","United States",{"type":82,"coordinates":83},"Point",[84,85],-122.71443,38.44047,{"lat":85,"lon":84},[88],{"name":89,"role":70,"phone":90,"phoneExt":52,"email":52},"Study Coordinator","707-521-3830",{"facility":92,"status":76,"city":93,"state":94,"zip":95,"country":80,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Orlando Health Cancer Institute ( Site 0108)","Orlando","Florida","32806",{"type":82,"coordinates":97},[98,99],-81.37924,28.53834,{"lat":99,"lon":98},[102],{"name":89,"role":70,"phone":103,"phoneExt":52,"email":52},"321-841-1869",{"facility":105,"status":76,"city":106,"state":107,"zip":108,"country":80,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"Saint Elizabeth Medical Center Edgewood ( Site 0112)","Edgewood","Kentucky","41017",{"type":82,"coordinates":110},[111,112],-84.58189,39.01867,{"lat":112,"lon":111},[115],{"name":89,"role":70,"phone":116,"phoneExt":52,"email":52},"859-301-4000",{"facility":118,"status":76,"city":119,"state":120,"zip":121,"country":80,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Washington University School of Medicine ( Site 0134)","St Louis","Missouri","63110",{"type":82,"coordinates":123},[124,125],-90.19789,38.62727,{"lat":125,"lon":124},[128],{"name":89,"role":70,"phone":129,"phoneExt":52,"email":52},"314-747-1171",{"facility":131,"status":76,"city":132,"state":133,"zip":134,"country":80,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"John Theurer Cancer Center at Hackensack University Medical Center ( Site 0101)","Hackensack","New Jersey","07601",{"type":82,"coordinates":136},[137,138],-74.04347,40.88593,{"lat":138,"lon":137},[141],{"name":89,"role":70,"phone":142,"phoneExt":52,"email":52},"551-996-5955",{"facility":144,"status":76,"city":145,"state":146,"zip":147,"country":80,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Providence Cancer Institute, Franz Clinic - Eastside ( Site 0107)","Portland","Oregon","97213",{"type":82,"coordinates":149},[150,151],-122.67621,45.52345,{"lat":151,"lon":150},[154],{"name":89,"role":70,"phone":155,"phoneExt":52,"email":52},"503-215-5696",{"facility":157,"status":76,"city":158,"state":159,"zip":160,"country":80,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Avera Cancer Institute- Research ( Site 0104)","Sioux Falls","South Dakota","57105",{"type":82,"coordinates":162},[163,164],-96.72796,43.54369,{"lat":164,"lon":163},[167],{"name":89,"role":70,"phone":168,"phoneExt":52,"email":52},"605-322-6900",{"facility":170,"status":76,"city":171,"state":172,"zip":173,"country":80,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"The University of Tennessee Medical Center ( Site 0120)","Knoxville","Tennessee","37920",{"type":82,"coordinates":175},[176,177],-83.92074,35.96064,{"lat":177,"lon":176},[180],{"name":89,"role":70,"phone":181,"phoneExt":52,"email":52},"865-305-8780",{"facility":183,"status":76,"city":184,"state":172,"zip":185,"country":80,"cosmosGeoPoint":186,"geoPoint":190,"contacts":191},"Lt. Col. Luke Weathers, Jr. VA Medical Center ( Site 0133)","Memphis","38105",{"type":82,"coordinates":187},[188,189],-90.04898,35.14953,{"lat":189,"lon":188},[192],{"name":89,"role":70,"phone":193,"phoneExt":52,"email":52},"901-351-3673",{"facility":195,"status":76,"city":196,"state":172,"zip":197,"country":80,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"SCRI Oncology Partners ( Site 7000)","Nashville","37203",{"type":82,"coordinates":199},[200,201],-86.78444,36.16589,{"lat":201,"lon":200},[204],{"name":89,"role":70,"phone":205,"phoneExt":52,"email":52},"844-482-4812",{"facility":207,"status":76,"city":208,"state":209,"zip":210,"country":80,"cosmosGeoPoint":211,"geoPoint":215,"contacts":216},"Houston Methodist Hospital - Houston Methodist Neal Cancer Center ( Site 0113)","Houston","Texas","77030",{"type":82,"coordinates":212},[213,214],-95.36327,29.76328,{"lat":214,"lon":213},[217],{"name":89,"role":70,"phone":218,"phoneExt":52,"email":52},"646-407-2086",{"facility":220,"status":76,"city":221,"state":222,"zip":223,"country":80,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"University of Virginia Health System ( Site 0122)","Charlottesville","Virginia","22908",{"type":82,"coordinates":225},[226,227],-78.47668,38.02931,{"lat":227,"lon":226},[230],{"name":89,"role":70,"phone":231,"phoneExt":52,"email":52},"434-924-4251",{"facility":233,"status":76,"city":234,"state":235,"zip":236,"country":237,"cosmosGeoPoint":52,"geoPoint":52,"contacts":238},"CEMIC ( Site 1903)","Caba.","Buenos Aires","C1431FWO","Argentina",[239],{"name":89,"role":70,"phone":240,"phoneExt":52,"email":52},"+5491160006609",{"facility":242,"status":76,"city":243,"state":235,"zip":244,"country":237,"cosmosGeoPoint":245,"geoPoint":249,"contacts":250},"Hospital Austral ( Site 1901)","Pilar","B1629AHJ",{"type":82,"coordinates":246},[247,248],-58.91398,-34.45867,{"lat":248,"lon":247},[251],{"name":89,"role":70,"phone":252,"phoneExt":52,"email":52},"+54911 38018573",{"facility":254,"status":76,"city":255,"state":256,"zip":257,"country":258,"cosmosGeoPoint":259,"geoPoint":263,"contacts":264},"FALP ( Site 0200)","Santiago","Region M. de Santiago","7500921","Chile",{"type":82,"coordinates":260},[261,262],-70.64827,-33.45694,{"lat":262,"lon":261},[265],{"name":89,"role":70,"phone":266,"phoneExt":52,"email":52},"56224205098",{"facility":268,"status":76,"city":255,"state":256,"zip":269,"country":258,"cosmosGeoPoint":270,"geoPoint":272,"contacts":273},"Pontificia Universidad Catolica de Chile ( Site 0202)","8330032",{"type":82,"coordinates":271},[261,262],{"lat":262,"lon":261},[274],{"name":89,"role":70,"phone":275,"phoneExt":52,"email":52},"+56934271024",{"facility":277,"status":76,"city":255,"state":256,"zip":278,"country":258,"cosmosGeoPoint":279,"geoPoint":281,"contacts":282},"Bradfordhill ( Site 0201)","8420383",{"type":82,"coordinates":280},[261,262],{"lat":262,"lon":261},[283],{"name":89,"role":70,"phone":284,"phoneExt":52,"email":52},"56229490970",{"facility":286,"status":76,"city":287,"state":288,"zip":289,"country":290,"cosmosGeoPoint":291,"geoPoint":295,"contacts":296},"Beijing Cancer Hospital ( Site 1604)","Beijing","Beijing Municipality","100142","China",{"type":82,"coordinates":292},[293,294],116.39723,39.9075,{"lat":294,"lon":293},[297],{"name":89,"role":70,"phone":298,"phoneExt":52,"email":52},"010-88121122",{"facility":300,"status":76,"city":301,"state":302,"zip":303,"country":290,"cosmosGeoPoint":304,"geoPoint":308,"contacts":309},"Southern Medical University Nanfang Hospital ( Site 1608)","Guangzhou","Guangdong","510515",{"type":82,"coordinates":305},[306,307],113.25,23.11667,{"lat":307,"lon":306},[310],{"name":89,"role":70,"phone":311,"phoneExt":52,"email":52},"+86 13632102245",{"facility":313,"status":76,"city":314,"state":302,"zip":315,"country":290,"cosmosGeoPoint":316,"geoPoint":320,"contacts":321},"Jiangmen Central Hospital ( Site 1611)","Jiangmen","529000",{"type":82,"coordinates":317},[318,319],113.08333,22.58333,{"lat":319,"lon":318},[322],{"name":89,"role":70,"phone":323,"phoneExt":52,"email":52},"+86 13702282382",{"facility":325,"status":76,"city":326,"state":327,"zip":328,"country":290,"cosmosGeoPoint":329,"geoPoint":333,"contacts":334},"The First Affiliated Hospital of Nanchang University ( Site 1610)","Nanchang","Jiangxi","330209",{"type":82,"coordinates":330},[331,332],115.85306,28.68396,{"lat":332,"lon":331},[335],{"name":89,"role":70,"phone":336,"phoneExt":52,"email":52},"+86079186319453",{"facility":338,"status":76,"city":339,"state":340,"zip":341,"country":290,"cosmosGeoPoint":342,"geoPoint":346,"contacts":347},"Shanghai East Hospital ( Site 1600)","Shanghai","Shanghai Municipality","200000",{"type":82,"coordinates":343},[344,345],121.45806,31.22222,{"lat":345,"lon":344},[348],{"name":89,"role":70,"phone":349,"phoneExt":52,"email":52},"021-20334534",{"facility":351,"status":76,"city":352,"state":353,"zip":354,"country":290,"cosmosGeoPoint":355,"geoPoint":359,"contacts":360},"Sichuan Cancer hospital. ( Site 1609)","Chengdu","Sichuan","610213",{"type":82,"coordinates":356},[357,358],104.06667,30.66667,{"lat":358,"lon":357},[361],{"name":89,"role":70,"phone":362,"phoneExt":52,"email":52},"18180900912",{"facility":364,"status":76,"city":365,"state":366,"zip":367,"country":290,"cosmosGeoPoint":368,"geoPoint":372,"contacts":373},"The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 1602)","Hangzhou","Zhejiang","310003",{"type":82,"coordinates":369},[370,371],120.16142,30.29365,{"lat":371,"lon":370},[374],{"name":89,"role":70,"phone":375,"phoneExt":52,"email":52},"+8657187236560",{"facility":377,"status":76,"city":378,"state":366,"zip":379,"country":290,"cosmosGeoPoint":380,"geoPoint":384,"contacts":385},"Taizhou Hospital of Zhejiang Province ( Site 1601)","Taizhou","317000",{"type":82,"coordinates":381},[382,383],121.43312,28.66266,{"lat":383,"lon":382},[386],{"name":89,"role":70,"phone":387,"phoneExt":52,"email":52},"0576-85199810",{"facility":389,"status":76,"city":390,"state":52,"zip":391,"country":392,"cosmosGeoPoint":393,"geoPoint":397,"contacts":398},"Rambam Health Care Campus ( Site 0602)","Haifa","3109601","Israel",{"type":82,"coordinates":394},[395,396],34.99928,32.81303,{"lat":396,"lon":395},[399],{"name":89,"role":70,"phone":400,"phoneExt":52,"email":52},"+97247772688",{"facility":402,"status":76,"city":403,"state":52,"zip":404,"country":392,"cosmosGeoPoint":405,"geoPoint":409,"contacts":410},"Sheba Medical Center ( Site 0601)","Ramat Gan","5265601",{"type":82,"coordinates":406},[407,408],34.81065,32.08227,{"lat":408,"lon":407},[411],{"name":89,"role":70,"phone":412,"phoneExt":52,"email":52},"+97235303030",{"facility":414,"status":76,"city":415,"state":52,"zip":416,"country":417,"cosmosGeoPoint":418,"geoPoint":422,"contacts":423},"Seoul National University Hospital ( Site 1402)","Seoul","03080","South Korea",{"type":82,"coordinates":419},[420,421],126.9784,37.566,{"lat":421,"lon":420},[424],{"name":89,"role":70,"phone":425,"phoneExt":52,"email":52},"82-2-2072-3559",{"facility":427,"status":76,"city":415,"state":52,"zip":428,"country":417,"cosmosGeoPoint":429,"geoPoint":431,"contacts":432},"Severance Hospital Yonsei University Health System ( Site 1403)","03722",{"type":82,"coordinates":430},[420,421],{"lat":421,"lon":420},[433],{"name":89,"role":70,"phone":434,"phoneExt":52,"email":52},"+82215991004",{"facility":436,"status":76,"city":415,"state":52,"zip":437,"country":417,"cosmosGeoPoint":438,"geoPoint":440,"contacts":441},"Asan Medical Center ( Site 1404)","05505",{"type":82,"coordinates":439},[420,421],{"lat":421,"lon":420},[442],{"name":89,"role":70,"phone":443,"phoneExt":52,"email":52},"+82230103215",{"facility":445,"status":76,"city":415,"state":52,"zip":446,"country":417,"cosmosGeoPoint":447,"geoPoint":449,"contacts":450},"Samsung Medical Center ( Site 1401)","06351",{"type":82,"coordinates":448},[420,421],{"lat":421,"lon":420},[451],{"name":89,"role":70,"phone":452,"phoneExt":52,"email":52},"02-3410-1795",{"facility":454,"status":76,"city":455,"state":456,"zip":457,"country":458,"cosmosGeoPoint":459,"geoPoint":463,"contacts":464},"Hospital Universitario Insular de Gran Canaria ( Site 1002)","Las Palmas de Gran Canaria","Las Palmas","35016","Spain",{"type":82,"coordinates":460},[461,462],-15.41573,28.10178,{"lat":462,"lon":461},[465],{"name":89,"role":70,"phone":466,"phoneExt":52,"email":52},"+34 928441738",{"type":468,"investigatorFullName":52,"investigatorTitle":52,"investigatorAffiliation":52,"oldNameTitle":52,"oldOrganization":52},"SPONSOR",[470],{"name":471,"class":6},"Daiichi Sankyo","100610439",false,"NCT07227597","A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","A Phase 1b\u002F2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has a histologically or cytologically confirmed diagnosis of extensive-stage small cell lung cancer (ES-SCLC)\n* For participants receiving gocatamig + ifinatamab deruxtecan (I-DXd) in maintenance only:\n\n  * Completed 3 to 4 cycles of platinum + etoposide chemotherapy with concurrent approved anti-programmed cell death 1\u002FLigand 1 (anti PD-1\u002FL1) as first line (1L) treatment of ES-SCLC within 6 weeks prior to enrollment\n  * No radiological disease progression per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)\n  * No other prior systemic ES-SCLC therapy allowed\n  * Rechallenge therapy counts as an additional line and leads to exclusion\n* For participants receiving gocatamig + I-DXd in induction and maintenance, or gocatamig + I-DXd in induction followed by gocatamig + atezolizumab in maintenance, or carboplatin + etoposide + atezolizumab in induction followed by atezolizumab in maintenance: No prior systemic ES-SCLC treatment allowed\n* Applicable to all participants: prior limited-stage small cell lung cancer (SCLC) is allowed if \\> 6 months have passed since the end of previous therapy and progression\n* Must be able to provide a pretreatment archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated\n* Measurable disease by RECIST 1.1 as assessed by the local site investigator\u002Fradiology. Lesions situated in a previously irradiated area are considered measurable if growth has been shown in such lesions since the completion of radiation\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures\n* Has any history of interstitial lung disease (ILD)\u002Fpneumonitis irrespective of steroid use, current ILD, ILD that cannot be ruled out by imaging at screening, or suspected ILD\n* Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses\n* Has history of clinically significant intracranial bleeding or spinal cord bleeding\n* Has active neurologic paraneoplastic syndrome\n* Has history of coronary\u002Fperipheral artery bypass graft and\u002For any coronary\u002Fperipheral angioplasty or clinically significant cardiovascular disease such as myocardial infarction, symptomatic congestive heart failure (CHF), and\u002For uncontrolled cardiac arrhythmia within 6 months before the first dose of study intervention\n* Has other uncontrolled or significant protocol specified cardiovascular disease\n* Has history of arterial thrombosis within 6 months before the first dose of study intervention\n* Has chronic liver disease\n* Has history of allogeneic tissue\u002Fsolid organ transplant\n* Has history of leptomeningeal disease\n* Is infected with human immunodeficiency virus (HIV) and has a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor\n* Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids\n* Has known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Has major surgery within 4 weeks or minor surgery within 2 weeks of allocation\u002Frandomization (or first dose), or is anticipated to require a major surgical procedure during the study","ALL","18 Years",{"count":481,"type":482},170,"ESTIMATED","INTERVENTIONAL",[485,486],"PHASE1","PHASE2","Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body.\n\nA standard (usual) treatment for ES-SCLC uses both chemotherapy and immunotherapy.\n\n* Chemotherapy is a treatment that works to destroy cancer cells or stop them from growing.\n* Immunotherapy is a treatment that helps the immune system fight cancer.\n\nGocatamig and I-DXd (short for ifinatamab deruxtecan) are study medicines. Researchers want to know if giving gocatamig and I-DXd together can treat ES-SCLC. Researchers will also look at giving the study medicines with standard treatment. Gocatamig is a T-cell engager therapy. I-DXd is an antibody drug conjugate.\n\n* T-cell engager therapy is a certain type of immunotherapy that uses T-cells to find and destroy cancer cells.\n* A T-cell is a type of white blood cell, which are cells that help the body fight infection.\n* An antibody drug conjugate (ADC) is a treatment that attaches to a protein on cancer cells and delivers treatment to destroy those cells.\n\nThe goals of this study are to learn:\n\n* About the safety of combining gocatamig and I-DXd and if people tolerate them together\n* If people who receive gocatamig and I-DXd have ES-SCLC respond, which means the cancer gets smaller or goes away",[489],"Small Cell Lung Cancer Extensive Stage","2026-06-24",{"date":492,"type":493},"2026-06-26","ACTUAL",{"date":495,"type":493},"2026-01-29",{"date":497,"type":482},"2030-12-30",{"name":5,"class":6},32]